Gene Therapy
iwNHL Session II: understanding and harnessing the immune microenvironment against lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 9th November 2022
iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 26th October 2022
Identifying high-risk myeloma and improving treatment strategies in these patients
Multiple myeloma is a heterogeneous disease, and despite recent advances in therapeutic agents, several patients still relapse after therapy and…
Date: 22nd September 2022
The need for more effective first-line therapies in MDS
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early…
Date: 7th September 2022
Myeloma 2022: day two highlights
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that…
Date: 2nd September 2022
The promise of CAR-T therapy in CLL and challenges in the field
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…
Date: 31st August 2022
T-cell engagers in multiple myeloma: current challenges and future outlooks
Several novel agents have been approved in the field of multiple myeloma and have greatly transformed the treatment landscape of…
Date: 24th August 2022
The importance of patient-reported outcomes in CAR-T recipients
CAR-T therapies have been approved for use in several hematological malignancies, and have greatly improved treatment options for patients, especially…
Date: 17th August 2022
CAR-T therapy in myeloma and lymphoma
CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable data…
Date: 12th August 2022
CAR-T therapy in AML: challenges and future outlooks
Acute myeloid leukemia (AML) is an aggressive and heterogeneous hematological malignancy that poses many challenges for diagnosis and treatment. While…
Date: 10th August 2022
The current state of CAR-T therapy in lymphoma
Over the last few decades, advances in immunotherapies including CAR-T therapy have revolutionized the treatment of patients with relapsed/refractory (R/R)…
Date: 5th August 2022
Myeloma treatment updates from EHA 2022
While multiple myeloma remains a challenging disease to treat, there have been several advances in the field over the years….
Date: 3rd August 2022